Annexon Bolsters GA Program with Month 24 Endpoint, GBS Data Support BLA
Annexon (ANNX) reported a quarter that sets up a pivotal second half: the strategic expansion of its geographic atrophy (GA) program and encouraging new GBS data. The company added a month 24 dual primary endpoint to the ARCHER II trial, a move that management frames as ‘playing offense’ while still expressing full confidence in the month 15 readout expected in Q4 2026. Alongside this, the first cohort of the FORWARD study in GBS—a group of 10 patients—showed rapid, clinically meaningful improvement in every case, supporting the planned U.S. BLA submission.
GA Program: A Strategic Expansion
The most significant change is the addition of a second primary endpoint at month 24 for geographic atrophy. This decision, announced on the call, means the study will evaluate the primary endpoint at both month 15 and month 24, with alpha split between the two. Management insists this strengthens the program without weakening the near-term readout. As Lloyd Clark put it:
The ‘halftime’ assessment revealed strong execution: enrollment exceeded target by 30 patients, discontinuation rates were under 10%, and dosing compliance was above 95%—all allowing the team to reallocate power to a later time point. This is a clear attempt to build a “moat” around the asset, as CEO Doug Love stated: “Adding the month 24 endpoint meaningfully strengthens the program and a potential $100 billion-plus franchise.” — Douglas Love, President · 2026-08-12 The move also aligns with regulatory feedback—both FDA and EMA have signaled that including month 24 efficacy data in the label would require a prospective allocation of alpha.We effectively went to the locker room at halftime as we were assessing the month 12 progress of the trial.
The decision does raise questions about confidence in month 15, but management was unambiguous. Lloyd Clark noted: “essentially, what we're doing here is we're using found money in terms of strong trial execution to add a secondary time point.” — Lloyd Clark, Executive (likely Chief Medical Officer or similar, involved in clinical trial discussions) · 2026-08-12 The company remains on track to report the DMC’s assessment of the month 15 endpoint in Q4 2026, with full analyses of two substudies expected in Q1 2027 if the primary is met. The stock dipped 3.6% in the days following the call (from a peak of $5.50), likely reflecting skepticism or profit-taking, but the strategic rationale is sound.
GBS: Compelling FORWARD Data
On the GBS front, Annexon presented data from the first cohort of the FORWARD study, which enrolls Western patients across the U.S. and Europe. All 10 patients treated with a single 30 mg/kg infusion of tanruprubart showed rapid improvement, including four bed-bound patients who regained the ability to walk within days. Jamie Dananberg highlighted: “every patient demonstrated rapid, clinically meaningful improvement in loss of strength within 4 days of treatment.” — Jamie Dananberg, Executive (likely involved in clinical or medical affairs) · 2026-08-12 These results mirror the Phase III data and support the planned BLA submission in Q4 2026. The company also noted ongoing constructive discussions with the FDA and EMA regarding the filing package. This program has the potential to be the first targeted therapy for GBS, a disease with no approved standard of care that meaningfully alters outcomes.
Financial Position and Runway
To support the expanding pipeline, Annexon entered a credit facility with Oxford Finance, providing up to $200 million in non-dilutive capital. This extends the company’s cash runway into 2028, a critical buffer as it prepares for commercial launches. The fundamentals reflect a disciplined ramp: Research and development expense fell 26% year-over-year to $36 million, aligning with a tightening of spending as programs approach registration. Meanwhile, the net loss narrowed: Net loss improved 19% year-over-year to $44 million. The company’s cash runway metric is also showing recovery: The cash runway ratio has improved to 3.8x, up 92% year-over-year, reflecting the new facility. This financial prudence gives the company flexibility to execute on its regulatory milestones.
Primary endpoint design remains the centerpiece of the GA strategy, and the company’s lesion growth narrative is evolving—management argues that protecting photoreceptors (measured by ellipsoid zone) is more important than traditional RPE lesion growth. As trial execution continues to exceed expectations, the month 24 analysis could provide a differentiated label. For a company with a market cap under $1B, the potential of a first-in-class GBS therapy and a vision-sparing GA drug is significant. The next six to eighteen months will be decisive.